Results 281 to 290 of about 650,104 (308)

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Lancet, The, 2021
Ian D Kirkwood, Siobhan Ng, Sze-Ting Lee   +2 more
exaly  

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs

Research and Reports in Urology, 2022
Fabio Turco, Silke Gillessen, Consuelo Buttigliero   +2 more
exaly  

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

British Journal of Pharmacology, 2021
Jiyuan Chen, Zhengjie Wu, Weihong Ding   +2 more
exaly  

Treatment of Castrate-Resistant Prostate Cancer

Journal of Urology, 2013
openaire   +2 more sources

Clinical development of novel therapeutics for castration‐resistant prostate cancer

Ca-A Cancer Journal for Clinicians, 2012
Matthew D Galsky, Alexander C Small, Che-Kai Tsao   +2 more
exaly  

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

Cell, 2018
Srinivas R Viswanathan, Gavin Ha, Jeremiah Wala   +2 more
exaly  

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer

Cancer Cell, 2019
Laura Cato, Irène Lee, Ilsa Coleman
exaly  

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Annals of Oncology, 2013
S North, Rhonda L Bitting, K N Chi
exaly  

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Annals of Oncology, 2013
C S Higano, O Hamid, H I Scher
exaly  

Metastatic castrate-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations, 2015
openaire   +2 more sources